ghk-cu hair growth human study microneedling + Topical Treatment Meta-Analysis (2024) — Research Summary ghk-cu human clinical trial hair

Intranasal bioavailability to the CNS is estimated at 1-3% of the administered dose low in absolute terms but sufficient for pharmacological effect because the target tissue (brain) receives drug directly without first-pass hepatic metabolism

2x 35mg preloaded pens totalling 70mg, combining the copper peptide with BPC-157 and TB-500

It is important to have blood work performed prior to beginning this medication to assess liver and kidney function as well as assist in identifying any additional underlying health conditions.

This is why including B12 in the compound is medically justified, not merely cosmetic

For a 180 pound individual, this represents approximately 2.5 mcg/kg, well within the range shown effective in animal studies

Convenient dosing: A single weekly subcutaneous dose is easier to keep up than daily regimens [3]